PUBLISHER: The Business Research Company | PRODUCT CODE: 1682055
PUBLISHER: The Business Research Company | PRODUCT CODE: 1682055
Chromatin immunoprecipitation (ChIP) sequencing is a powerful molecular biology technique employed to investigate the interactions between proteins and DNA within a cell, offering insights into the binding patterns of specific proteins, often transcription factors or other chromatin-associated proteins, to DNA in a genome-wide manner.
The main types of ChIP sequencing include DNase-sequencing and Faire-sequencing. DNase-sequencing, commonly known as DNase-seq, is a molecular biology technique designed to assess the accessibility of DNA within the genome. It utilizes various technologies such as targeted sequencing, re-sequencing, whole genome sequencing, and whole exome sequencing for pre-sequencing, sequencing, and data analysis. The applications of DNase-seq encompass consumables and reagents, services, and other related components. The technique finds usage in academic research institutes, clinical research institutes, hospitals and clinics, pharmaceuticals and biotechnology companies, among others.
The chromatin immunoprecipitation (ChIP) sequencing market research report is one of a series of new reports from The Business Research Company that provides chromatin immunoprecipitation (ChIP) sequencing market statistics, including chromatin immunoprecipitation (ChIP) sequencing industry global market size, regional shares, competitors with a chromatin immunoprecipitation (ChIP) sequencing market share, detailed chromatin immunoprecipitation (ChIP) sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the chromatin immunoprecipitation (ChIP) sequencing industry. This chromatin immunoprecipitation (ChIP) sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chromatin immunoprecipitation (ChIP) sequencing market size has grown rapidly in recent years. It will grow from $13.89 billion in 2024 to $15.6 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to understanding gene regulation, rise in epigenetics studies, data analysis and bioinformatics tools, cost reduction and scalability.
The chromatin immunoprecipitation (ChIP) sequencing market size is expected to see rapid growth in the next few years. It will grow to $25.37 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to industry investment and competition, clinical adoption and diagnostic applications, demand for biomarker discovery, rapid development in bioinformatics tools, expanded applications in drug discovery. Major trends in the forecast period include clinical translation and diagnostic applications, focus on histone modifications, application in novel research areas, advancements in sample preparation, multi-omics integration.
The growth of the chromatin immunoprecipitation (ChIP) sequencing market is expected to be driven by the increasing prevalence of prostate cancer. Prostate cancer, which originates in the prostate gland, is anticipated to contribute to the market's expansion. ChIP-seq plays a vital role in prostate cancer research by providing a comprehensive understanding of the molecular events influencing the disease. This information is crucial for advancing the understanding of its biology and developing more targeted therapeutic interventions. In January 2023, the American Cancer Society reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths in the US, emphasizing the significance of ChIP-seq in addressing this health concern.
The growth of the chromatin immunoprecipitation (ChIP) sequencing market is expected to be propelled by the increasing adoption of personalized medicine. Personalized medicine, which tailors medical decisions to individual patient characteristics, relies on identifying specific genetic or epigenetic markers associated with diseases. ChIP sequencing proves to be a powerful tool in mapping epigenetic modifications crucial for understanding the genetic basis of diseases. In 2022, the approval of 37 novel molecular entities by the FDA's Center for Drug Evaluation and Research, with 34% designated as tailored medications by the Personalized Medicine Coalition, highlights the role of ChIP sequencing in advancing personalized medicine.
Major companies in the chromatin immunoprecipitation (ChIP) sequencing market are concentrating on innovative technologies, such as hmqChIP-seq (high-throughput multiplex quantitative Chromatin Immunoprecipitation sequencing), to improve the efficiency and accuracy of epigenomic research. This focus is expected to drive advancements in drug discovery and personalized medicine. hmqChIP-seq is an advanced technology aimed at enhancing the study of epigenetic modifications throughout the genome. For instance, in June 2024, Epigenica, a Sweden-based life sciences technology company, launched its EpiFinder Platform, which incorporates patented hmqChIP-seq technology. This platform allows for high-throughput, multiplex quantitative analysis in epigenomic research, enabling researchers to generate 192 genome-wide profiles simultaneously from up to 24 samples. This innovative solution streamlines large-scale experiments with unprecedented speed and cost efficiency.
Major companies operating in the chromatin immunoprecipitation (chip) sequencing market report are F. Hoffmann La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Co., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Bio-Techne Corp., BGI Genomics Co. Ltd., Promega Corporation, GenScript Biotech Corporation, Abcam PLC, BioLegend Inc., Hamilton Co., Takara Bio Inc., Novogene Co. Ltd., Oxford Nanopore Technologies PLC, Porvair Sciences Ltd., Creative Biolabs Inc., Cell Signaling Technology Inc., GENEWIZ Inc., Zymo Research Corporation, CD Genomics, Active Motif Inc., Psomagen Inc., EpiCypher Inc.
North America was the largest region in the chromatin immunoprecipitation (ChIP) sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chromatin immunoprecipitation (chip) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the chromatin immunoprecipitation (chip) sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The chromatin immunoprecipitation (ChIP) sequencing market consists of revenues earned by entities by providing services such as ChIP sample preparation, library preparation and sequencing, bioinformatics analysis, customization and consultation, data interpretation and reporting, and quality control, and assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The ChIP sequencing market also includes sales of ChIP kits, antibodies, DNA library preparation kits, sequencing kits, chromatin shearing equipment, and epigenetic modification kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chromatin immunoprecipitation (ChIP) Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chromatin immunoprecipitation (chip) sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for chromatin immunoprecipitation (chip) sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chromatin immunoprecipitation (chip) sequencing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.